ResearcherMayo ClinicActive in the last 2 years

Hala Muaddi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9721-2808; OpenAlex author ID A5008455068. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2025: 1 paper

Papers 1

Financial Toxicity of Long-Term Survivors Who Underwent Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/jso.27871 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Andrea Zironda · 1 shared paper, 2025 · strength 0.24
- Paper Financial Toxicity of Long-Term Survivors Who Underwent Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. DOI 10.1002/jso.27871 ↗
Sean Patrick Cleary · 1 shared paper, 2025 · strength 0.24
- Paper Financial Toxicity of Long-Term Survivors Who Underwent Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. DOI 10.1002/jso.27871 ↗
Chi Zhang · 1 shared paper, 2025 · strength 0.24
- Paper Financial Toxicity of Long-Term Survivors Who Underwent Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. DOI 10.1002/jso.27871 ↗
Susanne Gray Warner · 1 shared paper, 2025 · strength 0.24
- Paper Financial Toxicity of Long-Term Survivors Who Underwent Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. DOI 10.1002/jso.27871 ↗
Michael L. Kendrick · 1 shared paper, 2025 · strength 0.24
- Paper Financial Toxicity of Long-Term Survivors Who Underwent Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. DOI 10.1002/jso.27871 ↗
Cornelius A. Thiels · 1 shared paper, 2025 · strength 0.24
- Paper Financial Toxicity of Long-Term Survivors Who Underwent Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. DOI 10.1002/jso.27871 ↗
Mark Joseph Truty · 1 shared paper, 2025 · strength 0.24
- Paper Financial Toxicity of Long-Term Survivors Who Underwent Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. DOI 10.1002/jso.27871 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.